New Research Reports

Kolimigundla, debottlenecking of existing plants, and additional grinding capacities. We value TRCL at 15x FY27E EV/EBITDA (vs. 3-year average of ~14x), arriving at a target price of 1,270, and downgrade the rating to Accumulate....

Strong history of product launches: Abbott India has been steadily growing led by consistent launches of both - own and Novo Nordisk’s products (marketing). Abbott India has launched over 100 products in India in the last 12 years and we expect the pipeline to stay strong.

The opportunities for the entire Indian capital market ecosystem over the next decade, with a rising financialization trend but low penetration (demat penetration at 15% vs 60%+ in the US), continue to be immense (highlighted in our capital market thematic report).

Retail Research

Retail Research

Asian Markets are trading mixed after Wall Street declined as investors await the Fed meeting decision. Nikkei and Hang Seng are both trading positively by 0.18% and 0.69%, respectively, whereas Shanghai is trading negatively by 0.09%.

We recommend a BUY on the stock with a target price of Rs 1,461/share, implying an upside of 10% from the CMP.

IPO NOTE

Newsletter

Controlled leverage with improving return ratios insight: JSL has consistently maintained a healthy balance sheet, with Net Debt to EBITDA below 1x, despite executing a significant capex of ~5,400 crore. With the commissioning of new capacities, it is expected to generate annual CFO >4,000 crore, enabling debt reduction in the coming years. Consequently,...